Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-22
2010-02-09
Ulm, John D. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S009100, C424S198100
Reexamination Certificate
active
07659243
ABSTRACT:
The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.
REFERENCES:
patent: 6706871 (2004-03-01), Ballinger et al.
Greenway et al., Neurology, 63(10): 1936-1938, Nov. 2004.
Del Bo et al., Neurobiology of Aging, 29(2):314-316, Epublished Nov. 17, 2006.
Itzeck J., Acta Clin Croat, 47(2):77-79, Jun. 2008.
Cronin et al., Neurobiology, 67:1833-1836, Nov. 2006.
Distler, J.H.W. et al., “Angiogenic and angiostatic factors in the molecular control of angiogenesis,”The Quarterly Journal of Nuclear MedicineSep. 2003; 47(3):149-161.
Greenway, M.J. et al., “A novel candidate region for ALS on chromosome 14q11.2,”NeurologyNov. 23, 2004; 63(10):1936-1938.
Greenway, M.J. et al., “Angiogenesis and ALS: Screening of a novel candidate gene in the Irish ALS population,”NeurologyApr. 2004; 62(7) Suppl. 5, p. A38.
Hayward, C. et al., “Molecular Genetic Analysis of the Apex Nuclease Gene in Amyotrophiclateral Sclerosis,”NeurologyJun. 19, 1999; 52(9):1899-1901.
Lambrechts, D. et al., “VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?”Trends in Molecular MedicineJun. 2004; 10(6):275-282.
Greenway Matt
Hardiman Orla
MacFarlane Stacey
Royal College of Surgeons in Ireland
Ulm John D.
Wolf Greenfield & Sacks P.C.
LandOfFree
Treatment of ALS and variants thereof consisting of primary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of ALS and variants thereof consisting of primary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ALS and variants thereof consisting of primary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187361